Articles by Lloyd Dunlap

New biotech startup focuses on next generation therapeutic peptides in oncology, immuno-oncology and immune diseases

Actinium selects Medpace as CRO for pivotal Iomab-B clinical trial

New research indicates the act of creating iPSCs for clinical use is unlikely to pass on cancer-causing mutations to patients

Spark adds new program for leading cause of inherited retinal disease

Alzheon announces efficacy analyses of prior tramiprosate Phase 3 studies on key clinical endpoints in Alzheimer’s disease

To include study of onapristone in combination with abiraterone

In reviewing the proposal, the Affymetrix board of directors notes that Origin appears to be a newly- formed shell entity with no assets of which Affymetrix is aware, and whose sole source of funding for the proposed transaction is $1.5 billion in potential debt commitments. Based on the analysis performed by Affymetrix' advisers, $1.5 billion falls materially short of the funds that would be required to complete the transaction,

Merger creates fast growing, global provider of sample prep, synthesis and bioanalytical tools for biotherapeutics discovery, development and manufacturing

Treatment with selective orexin-2 receptor antagonist MIN-202 improves symptoms of depression, independent from its effect on sleep

Rapastinel may sidestep cognitive deficits seen with ketamine

Envigo shares findings on the effectiveness of its rat models in examining susceptibility and attenuation to HSV-2 infection

With an initial $5-million donation, goal for Biogen and Target ALS is $20 million more in corporate funding

A gap caused during DNA replication could result in cancer-causing mutations

Rexahn progresses its Phase 2a clinical research in metastatic renal cell carcinoma

Data from four posters include results of Phase 1 study, patient case report and preclinical research